FdaApplication
NDA 021226
Identifiers
- fda_app_no: NDA021226
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2000-09-15 |
Revenue by product
KALETRA
| Period | Revenue |
|---|---|
| Q1 2020 | $86.0M* |
| Q4 2019 | $54.0M* |
| Q3 2019 | $74.0M* |
| Q2 2019 | $77.0M* |
| Q1 2019 | $78.0M* |
| Q4 2018 | $84.0M* |
| Q3 2018 | $88.0M* |
| Q2 2018 | $91.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KALETRA | LOPINAVIR; RITONAVIR | 133.3MG;33.3MG | CAPSULE;ORAL |
1 product